SIDEBAR: Oncology Drug Approvals in 2014

Get Permission

February 12, 2014: Ibrutinib (Imbruvica) receives accelerated approval for patients with chronic lymphocytic leukemia who have received at least one prior therapy. 

January 10, 2014: Trametinib (Mekinist) and dabrafenib ­(Tafinlar) receive approval for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Related Articles

Omacetaxine Mepesuccinate Receives Full FDA Approval for CML

The U.S. Food and Drug Administration (FDA) has granted full approval to omacetaxine mepesuccinate (Synribo) for injection. The full approval was based on the final analysis of two phase II trials that evaluated the efficacy and tolerability data of omacetaxine. The agent received an accelerated...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.